DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Kentucky Retirement Systems

Kentucky Retirement Systems grew its position in DexCom, Inc. (NASDAQ:DXCM) by 2.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,968 shares of the medical device company’s stock after purchasing an additional 691 shares during the quarter. Kentucky Retirement Systems’ holdings in DexCom were worth $3,398,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom in the 2nd quarter valued at $25,000. Sachetta LLC raised its stake in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares in the last quarter. DSM Capital Partners LLC acquired a new stake in DexCom during the 4th quarter worth $28,000. Crewe Advisors LLC acquired a new stake in DexCom during the 1st quarter worth $29,000. Finally, Riverview Trust Co acquired a new stake in DexCom during the 1st quarter worth $32,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other DexCom news, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,483 shares of company stock valued at $201,708. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on DXCM. Morgan Stanley cut their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. Robert W. Baird lifted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Finally, Wells Fargo & Company dropped their price objective on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Stock Up 3.5 %

Shares of NASDAQ:DXCM opened at $71.92 on Friday. The company has a market cap of $28.60 billion, a price-to-earnings ratio of 46.40, a PEG ratio of 2.12 and a beta of 1.18. The firm’s 50-day simple moving average is $79.06 and its 200-day simple moving average is $109.99. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.34 earnings per share. As a group, equities research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.